These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29719814)

  • 1. Transformation to small cell lung cancer after first-line afatinib treatment.
    Shiroyama T; Nasu S; Tanaka A; Takata S; Masuhiro K; Takada H; Morita S; Morishita N; Suzuki H; Okamoto N; Kawahara K; Hirashima T
    Respir Med Case Rep; 2018; 23():188-190. PubMed ID: 29719814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.
    Fang L; He J; Xia J; Dong L; Zhang X; Chai Y; Li Y; Niu M; Hang T; Li S
    Oncol Lett; 2017 Jul; 14(1):593-598. PubMed ID: 28693210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
    Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
    Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
    BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring
    Tanaka K; Nosaki K; Otsubo K; Azuma K; Sakata S; Ouchi H; Morinaga R; Wataya H; Fujii A; Nakagaki N; Tsuruta N; Takeshita M; Iwama E; Harada T; Nakanishi Y; Okamoto I
    Oncotarget; 2017 Sep; 8(40):68123-68130. PubMed ID: 28978102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
    Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M
    Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.
    Tanaka M; Ishii H; Moribuchi H; Naito Y; Matsuo N; Nakamura M; Tokito T; Azuma K; Yamada K; Hoshino T
    Invest New Drugs; 2018 Aug; 36(4):715-717. PubMed ID: 29546681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.
    Ma S; He Z; Fu H; Wang L; Wu X; Zhang Z; Wang Q
    Transl Lung Cancer Res; 2020 Feb; 9(1):139-143. PubMed ID: 32206560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of
    Miyamoto K; Ogino H; Kakimoto T; Matsumura Y; Haji K; Mitsuhashi A; Morita Y; Tsukazaki Y; Yabuki Y; Ozaki R; Yoneda H; Sato S; Hanibuchi M; Bando Y; Nokihara H; Nishioka Y
    Respir Med Case Rep; 2024; 51():102076. PubMed ID: 39027818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment.
    Kato Y; Tanaka Y; Hino M; Gemma A
    Respir Med Case Rep; 2019; 27():100837. PubMed ID: 31016132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
    Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
    J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report.
    Tani T; Naoki K; Asakura T; Hirano T; Suzuki S; Masuzawa K; Hasegawa H; Kuroda A; Yasuda H; Ishii M; Soejima K; Betsuyaku T
    Mol Clin Oncol; 2016 Oct; 5(4):488-490. PubMed ID: 27699048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
    Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
    Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature.
    Hui M; Uppin SG; Stalin BJ; Sadashivudu G
    Lung India; 2018; 35(2):160-163. PubMed ID: 29487254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with
    Oya Y; Yoshida T; Uemura T; Murakami Y; Inaba Y; Hida T
    Oncol Lett; 2018 Oct; 16(4):4219-4222. PubMed ID: 30214557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.
    Sonoda T; Nishikawa S; Sakakibara R; Saiki M; Ariyasu R; Koyama J; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ninomiya H; Ishikawa Y; Nishio M
    Respir Med Case Rep; 2018; 24():19-21. PubMed ID: 29977749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y; Wang Y; James M; Jeong JH; You M
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma.
    Alì G; Bruno R; Giordano M; Prediletto I; Marconi L; Zupo S; Fedeli F; Ribechini A; Chella A; Fontanini G
    Oncol Lett; 2016 Nov; 12(5):4009-4012. PubMed ID: 27895763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.